Insider Buying: ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Buys 60,000 Shares of Stock

ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster acquired 60,000 shares of the stock in a transaction on Friday, September 20th. The shares were purchased at an average price of $1.25 per share, for a total transaction of $75,000.00. Following the transaction, the director now directly owns 68,333 shares in the company, valued at $85,416.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

ProMIS Neurosciences Stock Performance

Shares of ProMIS Neurosciences stock opened at $1.31 on Thursday. The firm has a 50-day moving average of $1.39 and a 200-day moving average of $1.71. ProMIS Neurosciences, Inc. has a 52-week low of $0.95 and a 52-week high of $3.10. The stock has a market cap of $24.84 million, a PE ratio of -1.77 and a beta of 0.62.

ProMIS Neurosciences (NASDAQ:PMN) last announced its earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. Equities research analysts predict that ProMIS Neurosciences, Inc. will post -0.24 earnings per share for the current fiscal year.

ProMIS Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.